AT1413 induces ADCC and CDC of malignant myeloid cells in vitro. (A) AT1413 (open squares) induced ADCC and CDC of the AML cell line SH2 with EC50s of 1.1 nM (0.16 μg/mL) and 12.4 nM (1.86 μg/mL), respectively. Control antibody, AT1002 (red dots). (B) AT1413 (blue bars) induced ADCC of AML cells (SH2), but not of HAEC, HUVEC, and granulocytes. Control antibody, AT1002 (red bars). (C) Labeled SH2 cells were incubated with whole blood from a healthy individual and with AT1413 or rituximab. AML cells but not mononuclear cells were killed. As a control experiment, CD20⁺ Ramos cells were incubated with healthy whole blood and AT1413 or rituximab. PMN, polymorphonuclear cells.